UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

Journal of thoracic oncology, 2023-02, Vol.18 (2), p.181-193

2023

Volltextzugriff (PDF)

Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO study

BMC cancer, 2022-11, Vol.22 (1), p.1-1150, Article 1150

2022

Volltextzugriff (PDF)

Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples

Clinical lung cancer, 2017-11, Vol.18 (6), p.682-691.e5

2017

Volltextzugriff (PDF)

Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer

Oncoimmunology, 2019-06, Vol.8 (6), p.e1593810-e1593810

2019

Volltextzugriff (PDF)

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

Clinical cancer research, 2018-04, Vol.24 (7), p.1536-1545

2018

Volltextzugriff (PDF)

722 Imaging-guided preoperative localization of perisplenic isolated local recurrence of ovarian cancer using a combined harpoon and radioactive tracer technique

International journal of gynecological cancer, 2024-03, Vol.34 (Suppl 1), p.A65-A65

2024

Volltextzugriff (PDF)

Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer

Clinical cancer research, 2014-02, Vol.20 (4), p.938-950

2014

Volltextzugriff (PDF)

CD274 (PDL1) and JAK2 genomic amplifications in pulmonary squamous‐cell and adenocarcinoma patients

Histopathology, 2018-01, Vol.72 (2), p.259-269

2018

Volltextzugriff (PDF)

Non-bacterial thrombotic endocarditis in ROS1-rearranged lung cancer: a report of two cases

Translational lung cancer research, 2024-01, Vol.13 (1), p.179-185

2024

Volltextzugriff (PDF)

Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date

Cancer management and research, 2019-05, Vol.11, p.4893-4904

2019

Volltextzugriff (PDF)

732 Sertoli-leydig cell tumour a rare and challenging condition

International journal of gynecological cancer, 2024-03, Vol.34 (Suppl 1), p.A360-A360

2024

Volltextzugriff (PDF)

Impact of prehabilitation during neoadjuvant chemotherapy and interval cytoreductive surgery on ovarian cancer patients: a pilot study

World journal of surgical oncology, 2022-02, Vol.20 (1), p.46-46, Article 46

2022

Volltextzugriff (PDF)

Comprehensive NGS profiling to enable detection of ALK gene rearrangements and MET amplifications in non-small cell lung cancer

Frontiers in oncology, 2023-10, Vol.13, p.1225646

2023

Volltextzugriff (PDF)

Pre-existing tumor host immunity characterization in resected non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2023-07, Vol.181, p.107257-107257, Article 107257

2023

Volltextzugriff (PDF)

Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non–small-cell Lung Cancer: Implications of FISH-positive Patterns

Clinical lung cancer, 2019-07, Vol.20 (4), p.e421-e429

2019

Volltextzugriff (PDF)

Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting

Cancers, 2022-09, Vol.14 (18), p.4414

2022

Volltextzugriff (PDF)

Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer

JCO precision oncology, 2021-11, Vol.5 (5), p.93-102

2021

Volltextzugriff (PDF)

The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

Clinical & translational oncology, 2024-03, Vol.26 (7), p.1779-1789

2024

Volltextzugriff (PDF)

Multiple Brain Pseudoprogression in a Patient With NSCLC Treated With Pembrolizumab

JTO clinical and research reports, 2020-09, Vol.1 (3), p.100070, Article 100070

2020

Volltextzugriff (PDF)

A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer

ESMO open, 2019-07, Vol.4 (4), p.e000532-e000532, Article e000532

2019

Volltextzugriff (PDF)

Assessment of ALK Status by FISH on 1000 Spanish Non-Small Cell Lung Cancer Patients

Journal of thoracic oncology, 2014-12, Vol.9 (12), p.1816-1820

2014

Volltextzugriff (PDF)

Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC

JTO clinical and research reports, 2021-01, Vol.2 (1), p.100115-100115, Article 100115

2021

Volltextzugriff (PDF)

Complementary value of electron microscopy and immunohistochemistry in the diagnosis of non-small cell lung cancer: A potential role for electron microscopy in the era of targeted therapy

Ultrastructural pathology, 2019-11, Vol.43 (6), p.237-247

2019

Volltextzugriff (PDF)

1 – 25 von 91

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(81)
Mit Volltextzugriff
(77)

Publikationsform

Sprache

Englisch
(85)
Spanisch
(9)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(44)
Science & Technology
(44)
Oncology
(36)
Humans
(26)
Female
(18)
Male
(17)
Aged
(13)
Middle Aged
(13)
Respiratory System
(13)
Lung Neoplasms - Pathology
(12)
Lung Neoplasms - Genetics
(11)
Carcinoma, Non-Small-Cell Lung - Genetics
(10)
Immunotherapy
(10)
Adult
(9)
Cancer
(9)
Carcinoma, Non-Small-Cell Lung - Pathology
(9)
Lung Neoplasms - Drug Therapy
(8)
Mutation
(8)
Ovarian Cancer
(8)
Aged, 80 And Over
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO study

Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples

Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

722 Imaging-guided preoperative localization of perisplenic isolated local recurrence of ovarian cancer using a combined harpoon and radioactive tracer technique

Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer

CD274 (PDL1) and JAK2 genomic amplifications in pulmonary squamous‐cell and adenocarcinoma patients

Non-bacterial thrombotic endocarditis in ROS1-rearranged lung cancer: a report of two cases

Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date

732 Sertoli-leydig cell tumour a rare and challenging condition

Impact of prehabilitation during neoadjuvant chemotherapy and interval cytoreductive surgery on ovarian cancer patients: a pilot study

Comprehensive NGS profiling to enable detection of ALK gene rearrangements and MET amplifications in non-small cell lung cancer

Pre-existing tumor host immunity characterization in resected non-small cell lung cancer

Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non–small-cell Lung Cancer: Implications of FISH-positive Patterns

A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity

Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting

Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer

The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

Multiple Brain Pseudoprogression in a Patient With NSCLC Treated With Pembrolizumab

A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer

Assessment of ALK Status by FISH on 1000 Spanish Non-Small Cell Lung Cancer Patients

Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC

Complementary value of electron microscopy and immunohistochemistry in the diagnosis of non-small cell lung cancer: A potential role for electron microscopy in the era of targeted therapy

Suchergebnisse filtern